Independent directory Public ClinicalTrials.gov records United States
Clinical Trials Finder
Objective public record navigation
Search Results

Search by objective public record fields.

Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results are retrieved from ClinicalTrials.gov and synchronized into the directory. Search pages remain noindex by default.

Clear filters
ClinicalTrials.gov public records Last synced Sep 24, 2026, 9:05 PM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Showing 1–24 of 150 matching trials from the live ClinicalTrials.gov search.
Local D1 index available.
Filters: Condition: Type 2 Diabetes Treated With Insulin Clear all
Withdrawn Phase 4 Interventional

A Study of A Novel Approach to Titrate Basal Insulin (LY2963016) in Participants With Type 2 Diabetes

NCT04864977
View directory record Official record
Conditions
Type 2 Diabetes, Type 2 Diabetes Treated With Insulin
Interventions
Basal Insulin
Drug
Lead sponsor
Eli Lilly and Company
Industry
Eligibility
18 Years to 80 Years
Healthy volunteers
Healthy volunteers not accepted
Timeline
2021 – 2022
U.S. locations
1
States / cities
Boston, Massachusetts
Source: ClinicalTrials.gov public record
Updated Aug 23, 2021 · Synced Sep 24, 2026, 9:05 PM EDT
Recruiting Phase 3 Interventional

AMBITION 7: A Research Study Investigating How Well Zenagamtide Lowers Blood Sugar and Body Weight Compared to Insulin Glargine in People With Type 2 Diabetes and Increased Risk of Diseases That Affect the Heart and Blood Vessels Treated With 1-3 Other Diabetes Medications

NCT07797335
View directory record Official record
Conditions
Type 2 Diabetes, Cardiovascular Risk
Interventions
Zenagamtide, Insulin glargine U-100
Drug
Lead sponsor
Novo Nordisk A/S
Industry
Eligibility
45 Years and older
Enrollment
1,778 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2026 – 2028
U.S. locations
109
States / cities
Birmingham, Alabama • Fairhope, Alabama • Montgomery, Alabama + 91 more
Source: ClinicalTrials.gov public record
Updated Aug 31, 2026 · Synced Sep 24, 2026, 9:05 PM EDT
Completed Phase 4 Interventional Results available

Adding Exenatide to Insulin Therapy for Patients With Type 2 Diabetes and Non-Alcoholic Fatty Liver Disease

NCT01006889
View directory record Official record
Conditions
Nonalcoholic Fatty Liver Disease, Type 2 Diabetes Mellitus
Interventions
Exenatide
Drug
Lead sponsor
University of Florida
Other
Eligibility
18 Years to 70 Years
Enrollment
24 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2008 – 2010
U.S. locations
1
States / cities
San Antonio, Texas
Source: ClinicalTrials.gov public record
Updated Sep 27, 2016 · Synced Sep 24, 2026, 9:05 PM EDT
Completed Phase 2 Interventional Results available

A Research Study in People With Type 2 Diabetes to Compare Two Types of Insulin: Insulin 287 and Insulin Glargine

NCT03922750
View directory record Official record
Conditions
Diabetes Mellitus, Type 2
Interventions
Insulin icodec, Insulin glargine U100
Drug
Lead sponsor
Novo Nordisk A/S
Industry
Eligibility
18 Years to 75 Years
Enrollment
154 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2019 – 2020
U.S. locations
13
States / cities
Walnut Creek, California • Roswell, Georgia • Idaho Falls, Idaho + 6 more
Source: ClinicalTrials.gov public record
Updated Jan 17, 2022 · Synced Sep 24, 2026, 9:05 PM EDT
Recruiting Not applicable Interventional

Continuous Glucose Monitor Use in Pregnancy

NCT05317585
View directory record Official record
Conditions
Type 2 Diabetes Treated With Insulin, Pregnancy, High Risk
Interventions
Continuous Glucose Monitor, Routine Capillary Blood Glucose Monitoring (Fingerstick Glucose)
Device
Lead sponsor
University of Massachusetts, Worcester
Other
Eligibility
18 Years and older · Female only
Enrollment
180 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2024 – 2027
U.S. locations
1
States / cities
Worcester, Massachusetts
Source: ClinicalTrials.gov public record
Updated Aug 2, 2026 · Synced Sep 24, 2026, 9:05 PM EDT
Completed Phase 3 Interventional Results available

Efficacy and Safety in Subjects With Type 2 Diabetes Receiving Subcutaneous Basal Insulin and Prandial Inhalation of Technosphere/Insulin Versus Subcutaneous Premixed Insulin Therapy Over a 52-Week Treatment Period and a 4-Week Follow-up

NCT00309244
View directory record Official record
Conditions
Diabetes Type 2
Interventions
Technosphere® Insulin Inhalation Powder, 70% insulin aspart protamine suspension and 30% insulin aspart injection (rDNA origin)
Drug
Lead sponsor
Mannkind Corporation
Industry
Eligibility
18 Years to 80 Years
Enrollment
677 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2006 – 2008
U.S. locations
80
States / cities
Mobile, Alabama • Tucson, Arizona • Chula Vista, California + 54 more
Source: ClinicalTrials.gov public record
Updated Oct 15, 2014 · Synced Sep 24, 2026, 9:05 PM EDT
Recruiting Not applicable Interventional

Virtual Diabetes Care for Adults With Type 2 Diabetes on Medicaid and Insulin Therapy

NCT06814184
View directory record Official record
Conditions
Type 2 Diabetes
Interventions
app-based nurse-led virtual diabetes care
Behavioral
Lead sponsor
Rutgers, The State University of New Jersey
Other
Eligibility
18 Years to 90 Years
Enrollment
60 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2026 – 2028
U.S. locations
2
States / cities
New Brunswick, New Jersey
Source: ClinicalTrials.gov public record
Updated Jul 1, 2026 · Synced Sep 24, 2026, 9:05 PM EDT
Completed Phase 3 Interventional Results available

Evaluation of Insulin Glargine in Combination With Sitagliptin in Type 2 Diabetes Patients: EASIE Extension Trial

NCT00851903
View directory record Official record
Conditions
Diabetes Mellitus, Type 2
Interventions
Insulin Glargine, Sitagliptin, Metformin
Drug
Lead sponsor
Sanofi
Industry
Eligibility
35 Years to 71 Years
Enrollment
112 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2009 – 2011
U.S. locations
1
States / cities
Bridgewater, New Jersey
Source: ClinicalTrials.gov public record
Updated Oct 3, 2012 · Synced Sep 24, 2026, 9:05 PM EDT
Completed Phase 3 Interventional Results available

Comparison of NN5401 Plus Insulin Aspart With Insulin Detemir Plus Insulin Aspart in Type 1 Diabetes

NCT00978627
View directory record Official record
Conditions
Diabetes, Diabetes Mellitus, Type 1
Interventions
insulin degludec/insulin aspart, insulin detemir, insulin aspart
Drug
Lead sponsor
Novo Nordisk A/S
Industry
Eligibility
18 Years and older
Enrollment
548 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2009 – 2010
U.S. locations
30
States / cities
La Mesa, California • Lancaster, California • Mission Hills, California + 25 more
Source: ClinicalTrials.gov public record
Updated Mar 19, 2017 · Synced Sep 24, 2026, 9:05 PM EDT
Recruiting Not applicable Interventional

Patient Centered Multi-Agent Decision Support System (PCM-DSS) for Healthcare Providers

NCT07063420
View directory record Official record
Conditions
Type 2 Diabetes Treated With Insulin
Interventions
Continuous Glucose Monitor (CGM) + Patient Centered Multi-Agent Decision Support System (PCM-DSS), Continuous Glucose Monitor (CGM) + Usual Care
Other
Lead sponsor
Daniel Chernavvsky, MD
Other
Eligibility
18 Years and older
Enrollment
18 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2025 – 2026
U.S. locations
1
States / cities
Charlottesville, Virginia
Source: ClinicalTrials.gov public record
Updated Nov 12, 2025 · Synced Sep 24, 2026, 9:05 PM EDT
Completed Phase 3 Interventional Results available

A Study in Participants With Type 2 Diabetes Mellitus (AWARD-4)

NCT01191268
View directory record Official record
Conditions
Diabetes Mellitus, Type 2
Interventions
Insulin Glargine, LY2189265, Insulin Lispro
Drug
Lead sponsor
Eli Lilly and Company
Industry
Eligibility
18 Years and older
Enrollment
884 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2010 – 2012
U.S. locations
36
States / cities
Concord, California • La Mesa, California • Lancaster, California + 33 more
Source: ClinicalTrials.gov public record
Updated Oct 7, 2014 · Synced Sep 24, 2026, 9:05 PM EDT
Completed Not applicable Interventional

Examining The Role of CGM in T2DM

NCT01614262
View directory record Official record
Conditions
DIABETES MELLITUS, NONINSULIN-DEPENDENT, 2 (Disorder)
Interventions
Continuous Glucose Monitoring with treatment algorithm
Other
Lead sponsor
University of North Carolina, Chapel Hill
Other
Eligibility
18 Years to 70 Years
Enrollment
35 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2012 – 2014
U.S. locations
2
States / cities
Atlanta, Georgia • Chapel Hill, North Carolina
Source: ClinicalTrials.gov public record
Updated Apr 18, 2017 · Synced Sep 24, 2026, 9:05 PM EDT
Completed Phase 2 Interventional Results available

To Compare the Effect of a Subcutaneous Canakinumab Administration to Placebo in Patients With Impaired Glucose Tolerance or Patients With Type 2 Diabetes With Differing Baseline Diabetes Therapies

NCT01068860
View directory record Official record
Conditions
Type 2 Diabetes Mellitus, Impaired Glucose Tolerance
Interventions
Canakinumab 150 mg, Placebo to Canakinumab
Drug
Lead sponsor
Novartis
Industry
Eligibility
18 Years to 74 Years
Enrollment
246 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2010
U.S. locations
11
States / cities
Los Angeles, California • Santa Ana, California • Spring Valley, California + 7 more
Source: ClinicalTrials.gov public record
Updated Sep 4, 2011 · Synced Sep 24, 2026, 9:05 PM EDT
Completed Phase 3 Interventional Results available

A Trial Comparing the Efficacy and Safety of Insulin Degludec and Insulin Glargine 300 Units/mL in Subjects With Type 2 Diabetes Mellitus Inadequately Treated With Basal Insulin With or Without Oral Antidiabetic Drugs

NCT03078478
View directory record Official record
Conditions
Diabetes, Diabetes Mellitus, Type 2
Interventions
Insulin degludec, Insulin glargine
Drug
Lead sponsor
Novo Nordisk A/S
Industry
Eligibility
18 Years and older
Enrollment
1,609 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2017 – 2019
U.S. locations
156
States / cities
Anniston, Alabama • Birmingham, Alabama • Chandler, Arizona + 135 more
Source: ClinicalTrials.gov public record
Updated Jan 10, 2022 · Synced Sep 24, 2026, 9:05 PM EDT
Completed Phase 4 Interventional Results available

Dipeptidyl Peptidase-4 Inhibitor (Sitagliptin) Therapy in the Inpatients With Type 2 Diabetes

NCT01378117
View directory record Official record
Conditions
Type 2 Diabetes Mellitus, Hospitalization, Hyperglycemia
Interventions
Sitagliptin, glargine, lispro
Drug
Lead sponsor
Emory University
Other
Eligibility
18 Years to 80 Years
Enrollment
90 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2011 – 2012
U.S. locations
2
States / cities
Atlanta, Georgia
Source: ClinicalTrials.gov public record
Updated Dec 6, 2018 · Synced Sep 24, 2026, 9:05 PM EDT
Completed Phase 3 Interventional

Effect of Insulin Glargine in Insulin Naïve Subjects With Type 2 Diabetes on Oral Hypoglycemic Agent(s)

NCT00653341
View directory record Official record
Conditions
Diabetes Mellitus, Type 2
Interventions
insulin glargine, NPH human insulin
Drug
Lead sponsor
Sanofi
Industry
Eligibility
30 Years to 70 Years
Enrollment
764 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2000 – 2001
U.S. locations
1
States / cities
Bridgewater, New Jersey
Source: ClinicalTrials.gov public record
Updated Apr 19, 2009 · Synced Sep 24, 2026, 9:05 PM EDT
Completed Not applicable Interventional Results available

Reducing Treatment Risk in Older Adults With Diabetes

NCT04585191
View directory record Official record
Conditions
Type 2 Diabetes Treated With Insulin, Hypoglycemia, Primary Health Care, Polypharmacy
Interventions
Conversation Aid, Attention Control Educational Handout
Behavioral · Other
Lead sponsor
Kaiser Permanente
Other
Eligibility
75 Years and older
Enrollment
450 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2020 – 2024
U.S. locations
4
States / cities
San Francisco, California • San Leandro, California • Union City, California + 1 more
Source: ClinicalTrials.gov public record
Updated Mar 20, 2025 · Synced Sep 24, 2026, 9:05 PM EDT
Completed Phase 3 Interventional Results available

Efficacy and Safety of the Insulin Glargine/Lixisenatide Fixed Ratio Combination Versus Insulin Glargine in Patients With Type 2 Diabetes

NCT02058160
View directory record Official record
Conditions
Type 2 Diabetes
Interventions
Insulin glargine/lixisenatide (HOE901/AVE0010), Insulin glargine (HOE901), Metformin (Background Drug)
Drug
Lead sponsor
Sanofi
Industry
Eligibility
18 Years and older
Enrollment
736 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2014 – 2015
U.S. locations
108
States / cities
Birmingham, Alabama • Sun City, Arizona • Tempe, Arizona + 91 more
Source: ClinicalTrials.gov public record
Updated May 8, 2017 · Synced Sep 24, 2026, 9:05 PM EDT
Completed Phase 2 Interventional

A Trial of INS068 in Patients With Type 2 Diabetes Not Adequately Controlled With One or Two Oral Antidiabetics

NCT04663282
View directory record Official record
Conditions
Type 2 Diabetes
Interventions
INS068 injection, Insulin Degludec
Drug
Lead sponsor
Jiangsu HengRui Medicine Co., Ltd.
Industry
Eligibility
18 Years to 75 Years
Enrollment
179 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2021 – 2022
U.S. locations
15
States / cities
Huntington Park, California • Lincoln, California • Lomita, California + 10 more
Source: ClinicalTrials.gov public record
Updated Dec 20, 2022 · Synced Sep 24, 2026, 9:05 PM EDT
Completed Phase 4 Interventional Results available

Impact of Dietary Intervention on Weight Change in Subjects With Type 2 Diabetes

NCT01232491
View directory record Official record
Conditions
Diabetes, Diabetes Mellitus, Type 2
Interventions
Insulin detemir, Dietary regimen
Drug · Dietary Supplement
Lead sponsor
Novo Nordisk A/S
Industry
Eligibility
18 Years and older
Enrollment
611 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2010 – 2011
U.S. locations
76
States / cities
Birmingham, Alabama • Ozark, Alabama • Anaheim, California + 63 more
Source: ClinicalTrials.gov public record
Updated Apr 30, 2017 · Synced Sep 24, 2026, 9:05 PM EDT
Completed Phase 3 Interventional Results available

Efficacy and Safety of Lixisenatide Versus Placebo on Top of Basal Insulin and/or Oral Antidiabetic Treatment in Older Type 2 Diabetic Patients

NCT01798706
View directory record Official record
Conditions
Type 2 Diabetes
Interventions
Lixisenatide (AVE0010), Placebo, Antidiabetic background therapy
Drug
Lead sponsor
Sanofi
Industry
Eligibility
70 Years and older
Enrollment
350 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2013 – 2015
U.S. locations
14
States / cities
La Jolla, California • Norwalk, California • Miami, Florida + 10 more
Source: ClinicalTrials.gov public record
Updated Apr 17, 2017 · Synced Sep 24, 2026, 9:05 PM EDT
Completed Phase 2 Interventional Results available

Comparison of Two NN1250 Formulations Versus Insulin Glargine, All in Combination With Metformin in Subjects With Type 2 Diabetes

NCT00611884
View directory record Official record
Conditions
Diabetes, Diabetes Mellitus, Type 2
Interventions
insulin glargine, insulin degludec, metformin
Drug
Lead sponsor
Novo Nordisk A/S
Industry
Eligibility
18 Years to 75 Years
Enrollment
245 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2008
U.S. locations
18
States / cities
Inglewood, California • Los Angeles, California • Redlands, California + 14 more
Source: ClinicalTrials.gov public record
Updated Mar 2, 2017 · Synced Sep 24, 2026, 9:05 PM EDT
Completed Phase 2Phase 3 Interventional

Study of Two Doses of Oral HDV-Insulin and Placebo With Background Metformin Treatment in Patients With Type 2 Diabetes Mellitus

NCT00814294
View directory record Official record
Conditions
Diabetes
Interventions
placebo, Oral Hepatic Directed Vesicles (HDV)-Insulin (U-15), Oral Hepatic Directed Vesicles (HDV)-Insulin (U-5)
Drug
Lead sponsor
Diasome Pharmaceuticals
Industry
Eligibility
18 Years to 70 Years
Enrollment
239 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2008 – 2009
U.S. locations
40
States / cities
Muscle Shoals, Alabama • Litchfield Park, Arizona • Tucson, Arizona + 35 more
Source: ClinicalTrials.gov public record
Updated May 25, 2021 · Synced Sep 24, 2026, 9:05 PM EDT
Completed Phase 4 Interventional Results available

Efficacy Assessment of Insulin Glargine Versus LiraglutidE After Oral Agents Failure

NCT01117350
View directory record Official record
Conditions
Diabetes Mellitus, Type 2
Interventions
Insulin glargine, Liraglutide, Metformin
Drug
Lead sponsor
Sanofi
Industry
Eligibility
35 Years to 75 Years
Enrollment
978 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2010 – 2013
U.S. locations
45
States / cities
Birmingham, Alabama • Goodyear, Arizona • Phoenix, Arizona + 39 more
Source: ClinicalTrials.gov public record
Updated Apr 10, 2014 · Synced Sep 24, 2026, 9:05 PM EDT